Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 22,600 shares, a decline of 60.8% from the December 31st total of 57,600 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 175,600 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ADIL shares. Rodman & Renshaw started coverage on Adial Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $8.00 target price on the stock. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Adial Pharmaceuticals Stock Down 12.7 %

Shares of Adial Pharmaceuticals stock opened at $0.83 on Wednesday. The stock’s fifty day moving average is $1.04 and its 200-day moving average is $1.03. Adial Pharmaceuticals has a 12-month low of $0.72 and a 12-month high of $4.17.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.